Spectinomycin sulfate hydrate is a broad-spectrum antibiotic capable of inhibiting the growth of various Gram-positive and Gram-negative bacteria. It targets bacterial ribosomes specifically, thereby disrupting protein synthesis. Additionally, spectinomycin sulfate hydrate acts as a non-competitive inhibitor of td intron RNA, with a Ki of 7.2 mM.

Spectinomycin sulfate hydrate selectively inhibits protein synthesis in cells and Escherichia coli extracts. At a concentration of 50 μg/mL, the compound quickly and reversibly inhibits E. coli growth, immediately suppressing amino acid incorporation. At lower concentrations of 1 μg/mL or 3 μM, spectinomycin sulfate hydrate inhibits peptide synthesis directed by endogenous messenger RNA or MS-2 bacteriophage RNA in E. coli extracts, with a maximum inhibition rate of 70-80%. The compound prevents peptidyl tRNA from transitioning from the A-site to the P-site on the ribosome by inhibiting elongation factor G binding. Spectinomycin sulfate hydrate specifically interacts with residues G1064 and C1192 in 16S rRNA, potentially rendering it inactive. Additionally, it exhibits splicing inhibitory effects that are dependent on pH variations and Mg2+ concentrations, suggesting electrostatic interactions with intron RNA.

Spectinomycin sulfate hydrate was administered to 15-day-old Arbor Acres plus broiler chicks over a period of 9 days via intramuscular injection in the chest muscles, with dosages of 20 mg/kg, 60 mg/kg, and 100 mg/kg. At a dosage of 20 mg/kg, the compound demonstrated biosecurity as evidenced by assessments including complete blood count, biochemical parameters, histopathological examinations, clinical signs, body weight gain, and feed conversion ratio (FCR), indicating safety for healthy chicks. However, administration at 60 mg/kg resulted in minor toxicity. The primary elimination pathway for Spectinomycin sulfate hydrate administered intravenously at a single dose of 10 mg/kg is renal excretion, with approximately 55% excreted unchanged in the urine. Pharmacokinetic analysis revealed parameters including C0, AUC0-∞, Vd, CL, MRT, and T½ for both non-atrioventricular and a three-compartment model, highlighting the dimensions of its pharmacokinetic profile.